messag updat estim follow post result
smooth impact posit impact
revenu per manag remain neutral rate
estim fair valu rang per share
compani
revenu chang increas estim
respect
product revenu chang due sustain growth class
base iqvia npa data continu momentum trulic increas
estim per year peak year estim trulic
growth class off-set lower revenu lead product
jardianc accord estim per year estim portion
jardianc around also increas estim
tirzepatid peak sale base feedback kol see
potenti glp/gip combin provid ad advantag obes addit type
oper margin maintain oper margin assumpt
estim oper margin line compani guidanc estim peak
oper margin exist product continu grow provid
ep chang increas estim
respect
fair valu rang reflect forecast sale profit
use larg pharmaceut compani discount rate
upsid risk includ better expect efficaci toler result
tirzepatid interim success verzenio monarch studi better-than-expect
oper leverag success develop novel antibodi
treatment partner abcellera
downsid risk includ sustain price pressur diabet immunolog
potenti pricing/reb pressur emgal competit trulic market
novo ozemp rybelsu failur tirzepatid trial impact due
unforeseen situat like pandem
page analyst certif import disclosur
page analyst certif import disclosur
guggenheim secur llc estim compani report pipelin potenti catalystsag moa indicationtrialpotenti catalyststock impactour viewtimingmirikizumab anti inhibitor psoriasisphas oasi result middl inhibitor heart failur -hfrefphas emperor-reducedtop-lin inhibitor ulcer colitisphas lucent receptor type diabetesphas inhibitor heart failur -hfpefphas emperor-preservedtop-lin result late inhibitor alopecia areata sever severephas result late btk inhibitor previous treat chronic lymphocyt lymphoma cll /sllphase i/ii -bruinaddit impactmarket viewpositivenegativemagnitud pipelin potenti catalyst pcd primarycompletiondateasperclinicaltri gov global
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
